Thursday, July 9, 2026

Patent intelligence · US

US 10124109

Method and device for treating allergic reactions and difficult-to-manage respiratory diseases

granted A61KA61K31/137A61K9/0019
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 12
Applicant portfolio 201
Patent details — US 10124109
Jurisdiction
US
Status
granted
Grant date
Nov 13, 2018
Expiration
Nov 8, 2038
Claims
20
CPC classes
A61K, A61K31/137, A61K9/0019
View on Google Patents ↗

Quick answer

US 10124109 (Method and device for treating allergic reactions and difficult-to-manage respiratory diseases) is held by Pharmaceutical Design, LLC. Status: granted. Granted Nov 13, 2018. Expires Nov 8, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K31/137, A61K9/0019

More from Pharmaceutical Design, LLC

Related pharmaceutical patents in our USPTO index.

  1. US 12378245

    Crystalline forms of an RSK inhibitor

    PHOENIX MOLECULAR DESIGNS · Expires Jul 31, 2045

    granted
  2. US 12297243

    Methods and compositions for reducing the immunogenicity of chimeric notch receptors

    Cell Design Labs, Inc. · Expires May 8, 2045

    granted
  3. US 12291058

    Dispersions for additive manufacturing comprising discrete carbon nanotubes

    MOLECULAR REBAR DESIGN, LLC · Expires May 1, 2045

    granted
  4. US 12268695

    Betulin-containing birch bark extracts and their formulation

    Amryt Pharmaceuticals Designated Activity Company · Expires Apr 3, 2045

    granted
  5. US 12247004

    2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use

    Oxford Drug Design Limited · Expires Mar 6, 2045

    granted
  6. US 12065498

    Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same

    Cell Design Labs, Inc. · Expires Aug 15, 2044

    granted
  7. US 12005194

    Configurable oxygen concentrator and related method

    SEPARATION DESIGN GROUP LLC · Expires Jun 6, 2044

    granted
  8. US 11998571

    Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease

    DESIGNED CELLS CO., LTD. · Expires May 30, 2044

    granted

Frequently asked questions

What is US patent 10124109?

US 10124109 (Method and device for treating allergic reactions and difficult-to-manage respiratory diseases) is held by Pharmaceutical Design, LLC. Status: granted. Granted Nov 13, 2018. Expires Nov 8, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10124109?

Pharmaceutical Design, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 201 pharmaceutical patents for this assignee.

When does US 10124109 expire?

Our index shows an expiration date of Nov 8, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.